Table 1_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

Table 3_Integration analysis of microRNAs as potential biomarkers in early-stage lung adenocarcinoma: the diagnostic and therapeutic significance of miR-183-3p.docx by Guodong Huang (1595956)

“…Introduction<p>Lung adenocarcinoma (LUAD) poses a significant therapeutic challenge, primarily due to delayed diagnosis and the limited efficacy of existing treatments.…”

DIP grouping and aggregation system. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

DIP coding logic example. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

DIP pre-payment and provider behavior mechanism. by Chenxuan Zhu (22622476)

“…Total costs in the non-surgical group showed a decreasing trend post-DIP intervention (β₁ + β₃ = −3.12). …”

The computed weighted sum of type I (dark gray) and type II (light gray) errors ( by Farrokh Habibzadeh (12256529)

S1 Raw images - by Yoon Seok Nam (20678482)

“…The TSA-treated group exhibited a reduction in the levels of oxidative stress markers 4-Hydroxynonenal and 3-Nitrotyrosine, along with a decrease in inflammatory cytokines, in both the mouse cochlea and in vitro HEI-OC1 (House Ear Institute-Organ of Corti 1) cell and HEK (Human Embryonic Kidney)293T cells. …”

I Optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

ANOVA for I optimal design of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The kinetic release data of the optimized formula compared to drug suspension. by Randa Mohammed Zaki (21637175)

Results for fibrin dominant clots: (A) time to recanalize <i>in vitro</i> model; (B) relative clot reduction; (C) RBC release; (D) relative clot degradation rate. by Sandra Thalerová (11434762)

Composition of different formulations with their responses in I optimal design for optimization of Axitinib loaded Spanlastics. by Randa Mohammed Zaki (21637175)

The composition and validation of the optimized formula with its predicted responses according to I Optimal Design. by Randa Mohammed Zaki (21637175)

Nitrogen isotopes. by Sarah J. Noe (19846136)

Carbon isotopes. by Sarah J. Noe (19846136)

Mapping of transposon insertions in the selected mutants of <i>M</i>. <i>bovis</i> PG45. by Aga E. Gelgie (17661720)

Technical properties of tested UASs. by Marc Roswag (20598443)

“…However, despite the use of larger propellers for the multicopter UAS compared to previous studies, we observed a deterrence effect for all echolocation groups. …”

ASMR (A), ASDR (B), Age-Standardized Rate of YLDs (C), and Age-Standardized Rate of YLLs (D) of high alcohol use-related Stroke in both sexes combined in global in 2021. by Nannan Qian (10650782)

Image 2_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”

Image 4_Assessment of heart rate deceleration capacity, heart rate deceleration runs, heart rate acceleration capacity, and lipoprotein-related phospholipase A2 as predictors in in... by Yaping Wang (289641)

“…For this purpose, we measured and analyzed the predictive value of heart rate deceleration capacity (DC), heart rate deceleration runs (DRs), heart rate acceleration capacity (AC) along with the plasma levels of lipoprotein-associated phospholipase A2 (Lp-PLA2).…”